Related Experiment Video
Updated: Aug 8, 2026

A Method of Trigonometric Modelling of Seasonal Variation Demonstrated with Multiple Sclerosis Relapse Data
Published on: December 9, 2015
Between-hospital variation in discontinuation of treatment with dimethyl fumarate in multiple sclerosis
Hilde Norborg1, Stephan Bramow2, Jan Harald Aarseth3
1Department of Clinical Medicine, University of Bergen, Bergen, Norway; Neuro-SysMed, Department of Neurology, Haukeland University Hospital, Bergen, Norway.
Background:
In multiple sclerosis (MS), switching disease modifying treatment is associated with higher relapse rate, healthcare expenses, disease burden, and lower quality of life. We compared drug discontinuation rates of dimethyl fumarate (DMF) between hospitals in Denmark and Norway.
Method:
Data from national MS registries were analyzed, adjusting for sex, age, disease duration, Expanded Disability Status Scale, and baseline relapses. Between-hospital variation was assessed using median hazard ratios (MHR).
Results:
3368 patients with relapsing-remitting MS started DMF at all clinics in Denmark (n = 14) and at a subset of clinics in Norway (n = 6). A median of 44% discontinued DMF. Predictors for discontinuation were female sex, younger age, higher EDSS and number of relapses at baseline. There was a significant difference in the risk of discontinuation between hospitals. The MHR for discontinuation because of treatment failure attributed to treating hospital was 1.51(SE 0.120, p < 0.001) in Norway and 1.34 (SE 0.055, p < 0.001) in Denmark.
Conclusion:
Discontinuation rates of DMF in MS varies between hospitals, independent of patient characteristics.
Related Concept Videos
Drug Accumulation During Multiple Dosing: Intermittent IV Infusions
Multiple Sclerosis l: Introduction
Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Determination of Multiple Dosing Parameters: Loading and Maintenance Doses
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Nonlinear Pharmacokinetics: Dependence of Elimination Half-Life and Dose Clearance
A study on guinea pigs examined the...